

Individuals using assistive technology may not be able to fully access the information contained in this file. For assistance, please call 800-835-4709 or 240-402-8010, extension 1. CBER Consumer Affairs Branch or send an e-mail to: ocod@fda.hhs.gov and include 508 Accommodation and the title of the document in the subject line of your e-mail.

Errata

1. Page 46, Section 5.2, 2nd Paragraph:

Original: Additional exploratory subgroup analysis showed the same trend in subjects with baseline ALSFRS-R >25 (i.e., the “no floor effect” subgroup, per Definition 1) (N=67)

Corrected: Additional exploratory subgroup analysis showed the same trend in subjects with baseline ALSFRS-R >25 (i.e., the “no floor effect” subgroup, per Definition 1) (N=67) and in subjects whose ALSFRS-R item level had no value 0 at baseline (i.e., “no floor effect” subgroup, per Definition 3) (N=51).


2. Page 46, Section 5.2, 4th Paragraph:

Original: For a post-hoc subgroup of subjects whose ALSFRS-R item level had no value 0 at baseline (i.e., “no floor effect” subgroup, per Definition 3) (N=22), the Applicant further conducted post-hoc analyses using causal inference framework to study the relationship between change in CSF NfL levels and change in ALSFRS-R.

Corrected: For a post-hoc subgroup of subjects whose ALSFRS-R item level had no value 0 at baseline (i.e., “no floor effect” subgroup, per Definition 3), the Applicant further conducted post-hoc analyses using causal inference framework to study the relationship between change in CSF NfL levels and change in ALSFRS-R.

3. Page 48, Section 5.2, Figure 19A subplot titled “Subject with No Item level Floor Effect at Baseline (N=22)” updated to include placebo data as well.

Original: Subject with No Item level Floor Effect at Baseline (N=22)



Corrected: Subject with No Item level Floor Effect at Baseline (N=51)

